In vitro efficacy of ampelopsin against echinococcus granulosus and echinococcus multilocularis

10Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

The metacestode stage of Echinococcus granulosus and Echinococcus multilocularis cause cystic echinococcosis and alveolar echinococcosis, respectively, which result in severe medical and veterinary problems. In this study, as an exploration of novel treatment agents against echinococcosis, we demonstrated that ampelopsin (AMP), which is extracted from Ampelopsis grossedentata and has been clinically used for treatments of various types of diseases including cancers for a long time, exhibited profound in vitro effect against E. granulosus protoscoleces and E. multilocularis metacestodes. Furthermore, in vitro cytotoxicity assay also demonstrated that AMP at the effective dose against E. granulosus protoscoleces and E. multilocularis metacestodes did not show significant toxicity to human hepatocytes. These results suggest that AMP has the potential as an alternative agent against echinococcosis.

Cite

CITATION STYLE

APA

Xin, Q., Yuan, M., Li, H., Lu, J., Song, X., & Jing, T. (2019). In vitro efficacy of ampelopsin against echinococcus granulosus and echinococcus multilocularis. Journal of Veterinary Medical Science, 81(12), 1853–1858. https://doi.org/10.1292/jvms.19-0347

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free